Amgen Announces Bemarituzumab's Successful Phase 3 Results in FGFR2b+ Gastric Cancer
Amgen Inc. (NASDAQ:AMGN) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Amgen Inc. (NASDAQ:AMGN) reported that the Phase 3 FORTITUDE-101 trial achieved its primary endpoint.